Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats

Journal of Drug Targeting

Volumn 5, Issue 4, 1998, Pages 303-312

  Agrawal, Sudhir ^a   Zhang, Xueshu ^b   Cai, Qiuyin ^b   Kandimalla, Ekambar R ^a   Manning, Adrienne ^a   Jiang, Zhiwie ^a   Marcel, Tony ^c   Zhang, Ruiwen ^b  

^a HYBRIDON INC   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c TMC Development   (France)

Author keywords

Aspirin; Oligonucleotide; Pharmacokinetics; Phosphorothioate

Indexed keywords

ACETYLSALICYLIC ACID; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; HALF LIFE TIME; MALE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN BINDING; RAT;

EID: 0031668513     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10611869808995883     Document Type: Article

References (23)

1. Agrawal, S. (1996) Antisense Oligonucleotides: Towards Clinical Trials. Trends in Biotechnology, 14, 376-387.
2. Agrawal, S., Ahang, X., Lu, Z., Tamburin, M. J., Yan. J., Cai, H., Kiasio, R. B., Habus, I., Iyer, R. P., Wu, D. and Zhang, R. (1995a) Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem. Pharm., 50, 571-576.
3. Agrawal, S., Temsamani, J., Galbraith, W. and Tang, Y-J. (1995b) Pharmacokinetics of antisense oligonucleotides. Clin. Pharm., 28, 7-16.
4. Agrawal, S., Temsamani, J. and Tang, Y.-J. (1991) Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA, 88, 7595-7599.
5. Bayever, E., Iverson, P. L., Bishop, M. R., Sharp, J. G., Tewary, H. K., Arneson, M. A., Pirruccello, S. J., Ruddon, R. W., Kessinger. A., Zon, G. and Armitage, J. O. (1993) Systemic Administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for Acute Myelodysplastic Syndrome: Initial results of Phase I Trials. Antisense Res. Dev., 3, 383-390.
6. Chem, T. L., Miller, P., Ts'O, P. O. P and Colvin, O. M. (1990) Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single i.v. injection in mice. Drug Metab. Dispos., 18, 815-818.
7. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharm. Exp. Ther., 267, 1181-1190.
8. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intradermal administration to rats. J. Pharm. Exp. Ther., 267, 89-94.
9. 14C-labeled afovirsen sodium in patients with genital warts. Clin. Pharm. Ther., 56, 641-646.
10. He, X. M. and Carter, D. C. (1992) Atomic Structure and chemistry of human serum albumin. Nature, 358, 209-215.
11. Iverson, P. L., Matta, J., Tracewell, W. G. and Zon, G. (1994) Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in adult male rat following single injections and continuous infusion. Antisense Res. Dev., 4, 43-52.
12. Padmapriya, A. A., Tang, J. Y., Agrawal, S. (1994) Large Scale synthesis, purification and analysis of oligodeoxynucleotide phosphorothioates. Antisense Res. Dev., 4, 185-199.
13. Saijo, Y., Perlaky, L., Wang, H., Busch, H. (1994) Pharmacokinetics, tissue distribution and stability of antisense oligodeoxynucleoside phosphorothioate ISIS 33466 in mice. Oncology Res., 6, 243-249.
14. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharm., 45, 932-943.
15. 3H-labeled oligonucleotides. II. 3′-, 5′-Blocked oligonucleotides. Mol. Pharm., 47, 636-646.
16. Srinivasan, S. K. and Iversen, P. L. (1995) Review of in vitro pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J. Clin. Lab. Anal., 9, 129-137.
17. Srinivasan, S. K., Tewary, H. K. and Iversen, P. L. (1995) Phosphorothioate interactions with albumin and implications for potential drug interactions. Antisense Res. Dev., 5, 131-139.
18. Zhang, R., Diasio, R. B., Lu, Z., Liu, T., Jiang, Z., Galbraith, W. M. and Agrawal, S. (1995a) Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem. Pharm., 49, 929-939.
19. Zhang, X., Lu, Z., Diasio, R. B., Jiang, Z., Tan, W., Agrawal, S., Zhang, R. (1995b) Plasma- and serum-protein binding of antisense oligodeoxynucleotide phosphorothioates in experimental animals and humans. Proc. Am. Assoc. Cancer. Res., 36, 411.
20. Zhang, R., Lu, Z., Zhang, H., Diasio, R. B., Habus, I., Jiang, Z., Iyer, R. P., Yu, D. and Agrawal, S. (1995c) In vivo stability and metabolism of a hybrid oligonucleotide phosphorothioate in rats. Biochem. Pharm., 50, 571-576.
21. Zhang, R., Lu, Z., Zhang, X., Diasio, R., Liu, T., Jiang, Z. and Agrawal, S. (1995d) In vivo stability and disposition of a self-stabilized oligodeoxynucleotide in rats. Clin. Chem., 41, 836-843.
22. Zhang, R., Yan, J., Shahinian, H., Amin, G., Lu, Z., Liu, T., Saag, M. S., Jiang, Z., Temsamani, J., Martin, R. R., Schechter, P. J., Agrawal, S. and Diasio, R. B. (1995e) Pharmacokinetics of an anti-human immunodeficiency virus antisense oligonucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharm. Exp. Ther., 39, 929-939.
23. Zhang, R., Lu, Z., Zhang, X., Diasio, R., Liu, T., Jiang, Z. and Agrawal, S. (1996) Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleotide phosphorothioate in rats after intravenous administration. J. Pharm. Exp. Ther., 278, 971-979.